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Abstract
Background: In Pakistan, nearly half of children younger than 5 years are stunted, and 1 in 3 is
underweight. Micronutrient deficiencies, a less visible form of undernutrition, are also endemic. They
may lead to increased morbidity and mortality as well as to impaired cognitive and physical development.
Objective: To estimate the lifetime costs of micronutrient deficiencies in Pakistani children aged
between 6 and 59 months.
Methods: We develop a health economic model of the lifetime health and cost consequences of
iodine, iron, vitamin A, and zinc deficiencies. We assess medical costs, production losses in terms of
future incomes lost, and disability-adjusted life-years (DALYs). The estimation is based on large
population surveys, information on the health consequences of micronutrient deficiencies extracted
from randomized trials, and a variety of other sources.
Results: Total societal costs amount to US$46 million in medical costs, US$3,222 million in pro-
duction losses, and 3.4 million DALYs. Costs are dominated by the impaired cognitive development
induced by iron-deficiency anemia in 6- to 23-month-old children and the mortality caused by vitamin
A deficiency. Costs are substantially higher in poorer households.
Conclusions: Societal costs amounted to 1.44% of gross domestic product and 4.45% of DALYs in
Pakistan in 2013. These costs hinder the country’s development. They could be eliminated by
improved nutrition of 6- to 59-month-old children and public health measures. Our results may
contribute to the design of cost-effective interventions aiming to reduce micronutrient deficiencies in
early childhood and their lifetime consequences.
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Introduction
Micronutrient deficiencies (MNDs) are a serious
but often invisible form of undernutrition, also
called hidden hunger. MNDs increase the mor-
bidity and mortality in children younger than 5
years. They also impair a child’s cognitive
and physical development and long-term out-
comes, thus leading to adverse health outcomes,
lower productivity, and lower incomes in adult
life.1,2 Widespread MNDs will therefore hinder
a country’s economic development.
MNDs are endemic in children younger than
5 years in Pakistan with 43.8% with iron defi-
ciency anemia (IDA), 54.0% with vitamin A defi-
ciency (VAD), and 39.2% with zinc deficiency
(ZnD) in 2011. Among school-age children,
36.7% may be at risk of iodine deficiency (IoD).3
These high levels of deficiencies have been
recognized for decades, but except for a substan-
tial improvement in iodine status, very little prog-
ress has been made in eradicating them.3
The high costs of nutritional deficiencies and
the substantial economic benefits of nutritional
interventions have been previously assessed.4-6
However, there is still a need for a deeper under-
standing of the societal costs of MNDs in the
countries affected, as it may increase the aware-
ness of decision makers for their severe and
multiple consequences. It may also contribute to
the design of effective and cost-effective nutri-
tional interventions by helping to identify the
socioeconomic strata (SES), age-groups, and
micronutrients with the highest potential for cost
reduction in a specific population.
The aim of this study was to assess the societal
costs of MNDs in a birth cohort of Pakistani chil-
dren affected by MNDs between the age of 6 and
59 months. The micronutrients considered
include iodine, iron, vitamin A, and zinc. We
assessed medical costs, production losses in terms
of future incomes lost, and healthy life-years lost.
The study follows an incidence-based lifetime
cost approach and thus calculates cost conse-
quences of MNDs in childhood over the whole
lifetime of the children affected.
Methods
We developed a health economic simulation
model that estimates the lifetime health and cost
consequences of IoD, IDA, VAD, and ZnD in
6- to 59-month-old Pakistani children. Infants
younger than 6 months were excluded due to lack
of data. The model is an extension of a previously
published model7,8 to Pakistan and additionally
integrates the consequences of IoD and xer-
ophthalmia as a consequence of VAD. Figure 1
Figure 1. Overview of health economic model of societal costs of selected micronutrient deficiencies (MNDs).
The social costs of MNDs are calculated in a health economic model proceeding in 4 steps: Step 1 stratifies 6- to
59-month-old Pakistani children in 20 groups (by age-group and socioeconomic status). Step 2 assesses the levels
of MNDs in each of these groups. Step 3 assesses the health consequences of the current levels of MNDs. Step 4
assesses the societal costs of these health consequences in 3 cost dimensions.
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and the following sections give an overview of the
model and the data used. Appendix 1 illustrates
further details of the model.
The model is based on a variety of data
sources. They include 2 large population surveys
(the 2012-2013 Pakistan Demographic and
Health Survey [PDHS]9 and the 2011 Pakistan
National Nutrition Survey [NNS]3), a survey on
the treatment costs in Pakistan of diseases
induced by MNDs (see Appendix 2), data from
national and international agencies, and data
extracted from systematic reviews and other
publications.
Model Population
In a first step, we stratified the model population
of 6- to 59-month-old children by 10 SES and by
2 age-groups (6- to 23-month-old and 24-59-
month-old). The model population was obtained
from the PDHS 2012-2013, which is based on a
representative sample of 14 000 households.9
We stratified by age-groups because the 6- to
23-month period is part of the first 1000 days
of life, which have been identified as a crucial
period to establish a lasting foundation for
health.10 The 10 SES were built upon the distri-
bution of households across the deciles of a
wealth index calculated according to the PDHS
methodology.9 We adjusted all age-groups to the
average size of a birth cohort and then extrapo-
lated the sample size to the total population of
Pakistan in 2013.
Prevalence of MNDs
In a second step, we calculated the prevalence of
MNDs in each subgroup based on the Pakistan
NNS 2011, which covers a representative sample
of 30 000 households.3 The prevalence was deter-
mined with micronutrient-specific biomarkers
and World Health Organization (WHO) threshold
values (Table 1). The prevalence of IoD was
assessed with urinary iodine concentration (UIC)
from spot urine samples in school-age children.
Because there is substantial day-to-day variation
in spot UIC, a single UIC should generally not be
used to categorize the iodine status of individuals.
However, WHO states that the percentage of indi-
viduals in a population UIC distribution that are
below the UIC thresholds (Table 1) can be con-
sidered at risk for low-iodine intakes.11 The pre-
valence of IDA was based on the altitude-
adjusted hemoglobin (Hb) values, and the frac-
tion of anemia attributable to iron deficiency was
defined at 60%.12,13 The prevalence of VAD and
ZnD was based on the serum retinol and serum
zinc concentrations, respectively.
Health Consequences
In a third step, we modeled the relationship
between MNDs and their health consequences.
This information was extracted from systematic
reviews and primary studies examining the
effects on health outcomes of micronutrient sup-
plementation trials with 6- to 59-month-old chil-
dren. We assumed that the micronutrient
Table 1. Biomarkers for Micronutrient Status and Threshold Values for Deficiencies.a
Micronutrient Monitoring Indicators Threshold Values for Micronutrient Deficiencies Source
Iodine Urinary iodine concentration (UIC) Mild: UIC ¼ 50-99 mg/L
Moderate: UIC ¼ 20-49 mg/L
Severe: UIC < 20 mg/L
11
Iron Serum hemoglobin (Hb) Mild: Hb < 110 g/L
Moderate: Hb < 100 g/L
Severe: Hb < 70 g/L
14
Vitamin A Serum retinol 20 mg/dL 15
Zinc Serum zinc 60 mg/dL 3
IDA, iron deficiency anemia; VAD, vitamin A deficiency; ZnD, zinc deficiency.
aThe distribution of the biomarkers for IDA, VAD, and ZnD was calculated based on their means and standard deviations (SD)
and by assuming a normal distribution.
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supplements provided in these trials are able to
close the gap necessary to meet the micronutrient
requirements. The health consequences of the
MNDs can therefore be derived from the differ-
ence in the health outcomes between the interven-
tion groups and the control groups. This approach
has been previously proposed.16 Mortality was
modeled as a population attributable fraction of
all-cause mortality.17
Costs of Health Consequences
In a fourth step, we modeled the societal costs of
MNDs as the lifetime costs of a birth cohort exposed
to MNDs at the age of 6 to 59 months (Figure 2).
Someof thehealthconsequencesofMNDsare rever-
sible and will occur only in the 6- to 59-month age
period, while other consequences are permanent
(nonreversible). Medical costs arise as household
expenditures for the treatment of the diseases attrib-
uted to MNDs and were assessed in a survey con-
ducted by our group in 2015 in the districts of
Hyderabad and Faisalabad. The methods and results
of the survey are presented in Appendix 2.
Production losses arise due to lower future
wages as children affected by impaired cognitive
or physical development will be less productive
as adults. These losses were measured as future
gross income losses based on SES-specific
wages. Current wages according to the Interna-
tional Labor Organization18 were extrapolated to
the future by assuming an income growth equal to
the yearly average in the previous decade. Future
wage differences between SES were calculated
by adjusting the current income distribution9 for
the social mobility between SES according to a
recent study based on the Pakistan Panel House-
hold Survey.19 Production losses were discounted
to present values with a discount rate of 3%20 and
converted to US Dollars with the mean exchange
rate of 2013.
Life-years lived with disability and lost due
to premature mortality were measured in
disability-adjusted life-years (DALYs).21 Follow-
ing the recent practice by the Institute of Health
Metrics and Evaluation, we did not discount future
DALYs.21 Note that reporting both production
losses and DALYs does not lead to double count-
ing, as a number of health economic studies have
shown that measures of production losses and of
health-related quality of life do not overlap.22
Sensitivity Analysis
In order to test the robustness of the results, we
ran a probabilistic and univariate sensitivity anal-
ysis (SA). Although the univariate SA shows the
impact of the most important model parameters,
the probabilistic SA creates a range of possible
model outcomes. It also determines the confi-
dence intervals of the main model outcomes. The
model was implemented in R version 3.1.1.
Ethics Statement
The data sets used in this study were obtained
from the PDHS 2012-2013 and the NNS
2011.3,9 Ethical review of the analysis was not
Figure 2. Time dimensions of the health economic model. The health economic model follows an incidence-
based approach and assesses the lifetime costs of micronutrient deficiencies (MNDs) in a birth cohort exposed to
MNDs from the age of 6 to 59 months. These costs include reversible and permanent effects and are modeled
over the whole lifespan of the birth cohort. Future production losses are discounted to present value.
488 Food and Nutrition Bulletin 38(4)
considered necessary as per guidelines from the
National Bioethics Committee, Pakistan, as the
data set was anonymous and available for public
use with no identifiable information on the survey
participants. The survey used to assess medical
costs was approved by the National Bioethics
Committee, Pakistan (No.4-87/14/NBC-152/
RDC/434–2014).
Results
Model Population and Child Mortality
The model population consisted of 21.5 million
children stratified in 20 age and SES subgroups
(Table 2). The average size of a birth cohort was
4.7 million children with a higher number of chil-
dren per household in poorer SES. All-cause mor-
tality rate was almost 4 times higher in the
younger than in the older age-group and differed
substantially between the poorest and the wealth-
iest SES, with an 8 times higher mortality among
the poorest 6- to 23-month-old and a 6 times
higher mortality among the poorest 24- to 59-
month-old (Figure 3).
Prevalence of MNDs
The prevalence of MNDs was stratified by age-
group, SES, and degree of severity (Table 3, Fig-
ure 4). The overall prevalence of IoD was 37%
and ranged from 2.30% for severe IoD to 24.45%
Table 2. Distribution of Number of Children (in 1,000) of Birth Cohort by Age-Group and SES.a
SES (low to high)
1 2 3 4 5 6 7 8 9 10 Total
6- to 23-month-old 884 826 717 792 664 702 758 663 625 556 7186
24- to 59-month-old 1746 1633 1420 1569 1317 1395 1507 1320 1246 1111 14263
6- to 59-month-old 2630 2459 2138 2361 1980 2098 2264 1983 1871 1667 21449
Share of SES (%) 12 11 10 11 9 10 11 9 9 8 100
Average birth cohort 587 549 477 527 442 467 504 442 416 371 4782
aPopulation size, the share of children and the average size of the birth cohort by socioeconomic strata (SES) and age-group.
Households are split into deciles of equal size for the whole country. Authors’ calculations based on Pakistan Demographic and
Health Survey (PDHS).9
Figure 3. Yearly, all-cause mortality rates per 1000 children. The figure shows the smoothed all-cause mortality
rates by SES and age-group. Households are split into deciles of equal size for the whole country. Authors’
calculations based on PDHS.9 SES indicates socioeconomic strata; PDHS, Pakistan Demographic and Health Survey.
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for mild IoD. IDA affected 39% of children and
was higher in the 6- to 23-month-old group.
Nearly half of the children were affected by VAD
and 1 in 3 children by ZnD. Although prevalence
of IDA and VAD decreased with increasing
wealth, we could not stratify ZnD and IoD by SES
due to data limitations.
Health and Cost Consequences
The health and cost consequences of MNDs in
6- to 59-month-old children are summarized
in Figure 5 and Tables 4 and 5. IoD in this
age-group of children may lead to mental
impairement.11 Mild to severe IoD may cause
functional and/or structural changes in the
brain leading to reversible and to permanent
(nonreversible) loss of IQ points.23 As there are
no data quantifying the ratio of reversible to
permanent damage of IoD on brain develop-
ment, for the purposes of this analysis, we
assume that the permanent effect is equal to
one-third of the total effect on mental impair-
ment and occurs only in 6- to 23-month-old
Table 3. Prevalence of MNDs by Age-Group and Severity in % (SE).a
Severity
Age-
Group
Iodine
Deficiency
Iron Deficiency
Anemia
Vitamin A
Deficiency Zinc Deficiency
Overall 6-23
36.70 (0.115)
41.86 (0.074) 47.75 (0.074) 32.83 (0.073)
24-59 37.01 (0.070) 49.04 (0.071) 34.87 (0.059)
Mild 6-23
24.45 (0.109)
11.76 (0.060) No distinction by severity No distinction by severity
24-59 12.60 (0.058)
Moderate 6-23
9.94 (0.091)
26.37 (0.070)
24-59 22.41 (0.065)
Severe 6-23
2.30 (0.065)
3.73 (0.046)
24-59 2.00 (0.038)
Abbreviations: MNDs, Micronutrient deficiencies; IoD, iodine deficiency; IDA, iron deficiency anemia; UIC, urinary iodine
concentration.
aThe table reports the prevalence of MNDs by type of micronutrient, age-group, and severity (only for IoD and IDA). Due to
lack of data regarding the UIC in the 6-59-month-old children, school-age-children are being used as a proxy for the prevalence
of IoD. Author’s calculations based on National Nutrition Survey, 2011-2012.
Figure 4. Prevalence of iron-deficiency anemia and vitamin A deficiency by age-group, severity, and SES (%).
Households are split into SES deciles of equal size for the whole country. Authors’ calculation based on NNS
2011-2012. SES indicates socioeconomic strata; PDHS, Pakistan Demographic and Health Survey; NNS, Pakistan
National Nutrition Survey.
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children. We also assume that permanent loss of
IQ points leads to future production losses and
DALYs, whereas reversible loss of IQ points
leads only to current DALYs (see Appendix 1).
The health consequences of IDA vary by
severity and age-group. IDA may lead to
impaired cognitive development, low physical
activity, and increased all-cause mortality (severe
IDA only). Moderate and severe IDA may cause
permanent cognitive impairment in 6- to 23-
month-old children affecting their productivity
in adulthood. Although several studies have
found a substantial effect of iron deficiency on
cognitive ability,33-35 only Lozoff et al33 have
assessed the long-term effect on IQ and estimated
it separately for children in mid-income and low-
income households. Our model is based on the
lower effect estimated in the mid-income group,
as the higher effect in the low-income group
might be biased due to adverse circumstances not
purely attributable to IDA. IDA also reduces
physical activity leading to reversible DALYs.
Premature mortality due to severe IDA leads to
future production losses and DALYs.
The health consequences of VAD include xer-
ophthalmia and increased risk of diarrhea,
measles, and all-cause mortality.29 Bitot spot and
night blindness are the first and most pervasive
symptoms of xerophthalmia in young children.36
They lead to current DALYs but are fully rever-
sible with vitamin A supplements. Diarrhea and
measles lead to direct medical costs and DALYs.
Premature all-cause mortality leads to future pro-
duction losses and DALYs.
The health consequences of ZnD include
stunting and diarrhea.30 Stunting has a long-
Figure 5. Health and cost consequences micronutrient deficiencies. Numbers refer to the model parameters
which are described in Tables 4 and 5 (first number refers to the table. Second number refers to the line in the
table). Dotted lines represent long-term consequences.
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term negative effect on adult wages. The cost
consequences of diarrhea were calculated as for
VAD. Table 6 presents additional economic para-
meters used in the health economic model.
Societal Costs of MNDs
Combining the information on the prevalence of
MNDs with the information on the health and
cost consequences of these deficiencies, we esti-
mated the total lifetime costs of MNDs in 6- to
59-month-old children in Pakistan in 2013
(Table 7). The costs accounted for US$46 (95%
confidence interval [CI] 26.1-71.5) million in
medical costs, US$3,222 (95% CI 1135-7725)
million in production losses, and 3.4 (95% CI
2.5-4.4) million DALYs. They represent the life-
time costs of a birth cohort affected by IoD, IDA,
VAD, and ZnD between the age of 6 and 59
months and may also be interpreted as the costs
that could be prevented every year by completely
eliminating these MNDs in this age-group.
Costs were dominated by MNDs in 6- to 23-
month-old children, with 92.6% of production
losses and 79.9% of DALYs (Figure 6). The high
production losses in the 6- to 23-month-old
Table 4. Health Consequences of Micronutrient Deficiencies.a
Micronutrient
Deficiency Health Consequence
Effect Size
(RR; 95% CI)
Persistent
Effect
Number in
Figure 5 Source
Iodine deficiency
(IoD)
Cognitive impairment:
Mild IoD! borderline and
mild cognitive
impairment
Moderate and Severe IoD
! borderline, mild and
moderate cognitive
impairment
Mild IoD: loss of 2.25
IQ points in school-
age-children
Moderate IoD: loss of
5.25 IQ points in
school-age-children
Severe IoD: loss of
20.25 IQ points in
school-age-children
and adults
Partially 4.1 Authors’
calculations
based on24
SR
Iron deficiency
anemia (IDA)
Share of anemia caused by
iron deficiency
60% 4.2 12 SR; 13
6-23 month-old only:
Moderate IDA !
borderline cognitive
impairment
Severe IDA ! mild
cognitive impairment
Moderate and severe
IDA: IQ in adults
reduced by 9 IQ
points
Yes 4.3 25-27 GBD
Low physical activity Mild to severe IDA: all
children affected
No 4.4 26
All-cause mortality Severe IDA: RR 2.19 Yes 4.5 28 SR
Vitamin A
deficiency
(VAD)
Xerophthalmia: Bitot spot RR of 2.22 (1.64, 3.03) No 4.6 29 SR
Xerophthalmia: Night
blindness
RR of 3.13 (2.0, 4.76) No 4.7
Diarrhea RR of 1.18 (1.15, 1.22) No 4.8
Measles RR of 2.00 (1.49, 2.70) No 4.9
All-cause mortality RR of 1.32 (1.20, 1.45) Yes 4.10
Zinc deficiency
(ZnD)
Stunting ZnD reduces HAZ-
Score by 0.09
(0.13, 0.06)
Yes 4.11 30SR
Diarrhea RR of 1.15 (1.12, 1.18) No 4.12
Abbreviations: GBD, global burden of diseases study; RR, relative risk; SR, systematic review; R, review.
aEffect sizes were extracted from the literature (see last column). Health consequences are assumed to be equal for both age-
groups, with the exception of the permanent cognitive impairment due to IoD and the cognitive impairment due to IDA.
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Table 5. Cost Consequences of Adverse Health Effects.
Health
Consequence Cost Category Type and Size of Effect
Number in
Figure 5 Source
Cognitive
impairment
Production
losses (future)
1 SD reduction of the cognitive score leads to
a reduction of adult wage by 8%
5.1 31
DALYs Borderline intellectual functioning: DW 0.011
Mild intellectual disability: DW 0.043
Moderate intellectual disability: DW 0.1
5.2 27 GBD
Low physical
activity
DALYs Mild anemia: DW 0.004
Moderate anemia: DW 0.052
Severe anemia: DW 0.149
5.3 27 GBD
Bitot spot DALYs Moderate distance vision impairment: DW
0.031
5.4 27 GBD
Night
blindness
DALYs Moderate distance vision impairment: DW
0.031
5.5 27 GBD
Diarrhea Medical costs Cost per episode: 438 PKR (US$5)
Average duration of diarrhea: 5 days
5.6 Survey by authors
32 GBD
DALYs Moderate diarrhea: DW 0.188 5.7 27 GBD
Measles Medical costs Cost per episode: 451 PKR (US$4.4)
(assumed to equal the costs of respiratory
diseases)
Average duration of measles: 10 days
5.8 Survey by authors
32 GBD
DALYs Severe infectious disease: DW 0.133 5.9 27 GBD
Stunting Production
losses (future)
1% decrease in height leads to a reduction of
adult wage by 8.06% (average height of
adults is 156.5 cm)
5.10 4
DALYs The last published DW for stunting was in the
GBD 1990 and equaled 0.002. Based on the
new methodology of the GBD 2010/2013
this DW is now equal to zero.
Abbreviations: DW, disability weight; GBD, global burden of diseases study; DALYs, disability-adjusted life-years.
Table 6. Economic Model Parameters.
Economic Parameter Value Source
Life expectancy 66.6 years 37
Monetary discount rate 3% 38
DALY discount rate 0% 39
Income growth (past 10 years) 2.44% 40
Begin and end of working life (years) 15; 65 41
Labor market participation (%) 56.4% 42
Unemployment rate (%) 5.1% 43
Nominal daily wage (US$) US$5.7 18
Future income share of the population currently in a certain quintile Quintile Share of income 19
1st 17.0
2nd 17.6
3d 20.0
4th 20.6
5th 24.8
Abbreviation: DALYs, disability adjusted life years.
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Table 7. Total Costs by Cost Category, Time Dimension, MND, and Age-Group.a
Micronutrient
Deficiency
Medical
Costs, US$m
Production Losses,
US$m
DALYs
Years Lived with
Disability (1000)
Years of Life
Lost (1000) DALYs (1000)
Future Mortality Total Current Future Mortality Total
6- to 23-month-old
IDA 2148 104 2252 145 1392 235 1772
Vitamin A 13 312 312 9 696 705
Zinc 6 11 11 4 4
Iodine 407 407 12 255 266
Total 19 2566 417 2983 169 1647 931 2747
24- to 59-month-old
IDA 31 31 216 67 283
Vitamin A 16 173 173 12 367 379
Zinc 10 34 34 6 6
Iodine 23 23
Total 26 34 205 239 257 434 691
6- to 59-month-old
IDA 2148 136 2284 361 1392 302 2055
Vitamin A 29 486 486 21 1063 1084
Zinc 16 45 45 10 10
Iodine 407 407 34 255 289
Total 46 2600 622 3222 426 1647 1365 3438
Abbreviations: IDA, iron deficiency anemia; MND, micronutrient deficiency.aCurrent costs occur at 6 to 59 months of age, while
future costs occur after the age of 5. The blank spots in the table show that the MNDs do not produce any costs in these
categories and not that these costs have not been considered.
Figure 6. Production losses and DALYs by micronutrient deficiency and cost category (share of respective total).
Shares of the production losses (A) and DALYs (B) by age-group (6- to 23-month-old and 24-59-month-old), type
of micronutrient deficiency and type of cost (current, future life, and mortality). Areas in black represent minor
cost categories. IDA, iron deficiency anemia; IoD, iodine deficiency; VAD, vitamin A deficiency; ZnD, zinc
deficiency; mort, mortality; fut, future; DALYs, disability adjusted life years.
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children were due to the impaired cognitive
development induced by IDA and IoD. The IDA
was responsible for over two-thirds of all produc-
tion losses and over half of all DALYs. The VAD
and IoD were respectively the second and third
most important causes for both production losses
and for DALYs. ZnD played only a minor role for
production losses and was negligible for DALYs.
The comparison between the societal costs of
MNDs in children living in the poorer andwealthier
households is presented in Figure 7. Costs were
higher in poorer households due to the higher pre-
valence and severity of deficiencies and the higher
number of children. Differences were particularly
strong for VAD with 4 times higher production
losses and 6 times higher DALYs in the poorest
than in the wealthiest third of households.
Results of SA
The tornado diagrams show the effect of a 10%
increase or decrease in the model parameters
(Figure 8). Production losses were most influ-
enced by the discount rate, the work-related para-
meters (work force participation rate, wage,
income growth), parameters relating to the effect
of IDA on cognition, and by the relative risk of
mortality with VAD. DALYs were most influ-
enced by the relative risk of mortality with VAD
and the parameters related to the impact of IDA
(share of anemia attributable to IDA, disability
weights of intellectual disability, and relative risk
of mortality with IDA).
For the probabilistic SA, we randomly varied
all model parameters within predefined distribu-
tions and then ran the model 10 000 times. Where
information on the variability of the parameters
was not available from the literature, we chose an
SD equaling 20% of the mean. Figure 9 shows the
distribution of total production losses and total
DALYs together with 95% CIs according to the
multivariate SA. The CIs around our estimates
are relatively narrow with 95% of all model runs
demonstrating production losses between US$1.1
and US$7.6 billion and 95% of DALYs between
2.5 and 4.4 million DALYs.
Discussion
We assessed the societal costs of MNDs in 6- to
59-month-old Pakistani children in 2013. The
costs were calculated as the lifetime cost conse-
quences of the current levels of iodine, iron, vita-
min A, and zinc deficiencies in a yearly birth
cohort. Total societal costs amounted to medical
costs of US$46 million for the treatment of illness
attributable to MNDs, to production losses of
US$3,222 million due to future incomes lost, and
to 3.4 million DALYs due to premature deaths
and years lived with disability. These costs
Figure 7. Production losses and DALYs due to iron deficiency anemia and vitamin A deficiency by socioeconomic
strata. Households are split into deciles of equal size for the whole country. The societal costs of zinc deficiency
and iodine deficiency are not represented as their prevalence could not be calculated by socioeconomic strata.
IDA, iron deficiency anemia; VAD, vitamin A deficiency; DALYs, disability adjusted life years.
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Figure 8. Univariate sensitivity analysis of production losses and DALYs. Dark blue bars show the effect of a 10%
increase in a parameter, while light blue bars show the effect of a 10% decrease in a parameter. RR, relative risk;
DW, disability weight; IoD, iodine deficiency; IDA, iron deficiency anemia; VAD, vitamin A deficiency; ZnD, zinc
deficiency; DALYs, disability adjusted life years.
Figure 9.Multivariate sensitivity analysis by type of societal cost. Distribution of total production losses and total
DALYs in 10 000 model runs. The dotted lines represent 95% confidence intervals. DALYs indicate disability
adjusted life years.
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represent a substantial burden for Pakistan and
correspond to 1.44% of GDP in 2013 lost due to
lower future productivity and to 4.45% of the
overall burden of 77.3 million DALYs in
2013.21 These costs can be interpreted as the costs
that could be prevented every single year if
MNDs could be completely eliminated in 6- to
59-month-old children.
Costs occurring at the age of 6 to 23 months
were substantially higher than those at the age of
24 to 59 months because of the higher prevalence
of MNDs and the more severe health conse-
quences at younger age. The same reasons led
to higher costs in poorer households. However,
costs were substantial even in the wealthiest
household decile. IDA had the most severe cost
consequences accounting for two-thirds of total
costs. The costs of VAD and IoD were also sub-
stantial, while the costs of ZnD were limited.
Production losses were dominated by future
income losses due to impaired cognitive and
physical development. They affect the country’s
economic growth and contribute to an
undernutrition-based poverty trap in which chil-
dren born in poor households are more likely to
become poor parents themselves.
Our study is based on a health economic model
simulating the lifetime consequences of MNDs in
young children by combining information from
clinical and epidemiological studies with eco-
nomic data.44 The model incorporates the cur-
rently available evidence on the prevalence of
MNDs in Pakistan, on their health consequences
in young children, and on their long-term effects.
The model might be criticized for the long causal
chains linking MNDs in early childhood to health
and cost outcomes over the whole lifespan. How-
ever, there is no alternative to this approach, as
randomized controlled studies tracking outcomes
over such a long time period are not available.
A previous study has estimated the lifetime
consequences of IDA in Pakistani children on
production losses at 0.75% of GDP in 1996.45
This result is of the same magnitude as ours,
although it based on older literature on the impact
of IDA on cognition and not limited to 6- to 59-
month-old children.
Our model differs from other epidemiological
models describing the consequences of MNDs
such as the Life Saved Tool46 or the PROFILES
model,47 as it considers morbidity as well as mor-
tality and assesses the cost consequences in the 3
dimensions (medical costs, production losses, and
DALYs). Furthermore, it differentiates by the
socioeconomic status of households and between
6- to 23-month-old and 24- to 59-month-old chil-
dren. We believe that this model is particularly
well suited to capture the multiple often irrever-
sible health and cost consequences of MNDs in
these children.
Several limitations of our analysis should be
recognized. First, the methods used to assess the
prevalence of IoD are a major source of uncer-
tainty. The prevalence of IoD was measured with
the proxy of a spot UIC in school-age children
due to lack of data on 6- to 59-month-old chil-
dren. The high day-to-day, within-person var-
iance in UIC may lead to an overestimation of
the prevalence of IoD and of its cost conse-
quences. However, the magnitude of this overes-
timation is not clear, as it depends on the iodine
intake from children’s diet. Second, we could not
consider all the MNDs which may affect 6- to 59-
month-old children but only those that were
assessed in the 2011 NNS. The survey did, for
example, not assess the folate and vitamin B 12
status of children. The presence of relevant defi-
ciencies of these micronutrients would lead an
underestimation of the costs of MNDs. Third,
we could only consider those health conse-
quences that had been investigated and were iden-
tified in the micronutrient supplementation trials.
Particularly, the long-term health consequences
are rarely assessed in these trials, which may lead
to an underestimation of the costs of MNDs.
Fourth, a possible overlap of the effect of single
MNDs on the same health outcome could not be
determined as in the case of the effect of IDA and
IoD on cognitive development. This lack of con-
trol for a possible overlap may lead to an over-
estimation of costs.
The high levels of MNDs in Pakistan have
been recognized for decades, but with the excep-
tion of IoD, very little progress has been made in
eradicating them.3 Although economic growth
may contribute to improve the nutritional content
of diets, it is not sufficient to solve the problem as
illustrated by the considerable levels of MNDs in
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children living in relatively wealthy Pakistani
households. The micronutrient status of the pop-
ulation must thus be improved by increasing
micronutrient intake through food fortification
and supplementation.
The Pakistan Standards and Quality Control
Act has issued specifications for the mass fortifi-
cation of staple foods such as wheat flour, edible
oil and ghee, and iodized salt.48 So far, only
iodized salt has been successful by reaching a
household coverage of 69% in 2011.3 Efforts for
the mass fortification of other staple foods, such
as the fortification of edible oil with vitamin A or
of wheat flour with iron and folate, have been
largely unsuccessful due to weak legislative sup-
port and a poor regulatory environment.48 The
provision of micronutrient supplements to popu-
lations with particularly high nutritional needs is
another strategy for reducing MNDs.49 Vitamin A
supplementation has reached a high coverage in
6- to 59-month-old children in Pakistan with
72%.9 However, the persistently high levels of
VAD among these children show that supplemen-
tation, although effective in controlled trials, may
not be sufficient.
Our results confirm the urgent need for poli-
cies aiming at an improvement in the micronutri-
ent status of 6- to 59-month-old children.
Interventions should in particular target 6- to
23-month-old children, as social costs of MNDs
are dominated by the costs occurring in this age-
group. Such policies may include the promotion
of dietary diversity and complementary feeding,
food fortification as well as multiple micronutri-
ent supplementation.49 Furthermore, interven-
tions aiming to eradicate MNDs in young
children should not only be aimed at children but
also at their mothers, as the low body stores of
micronutrients in young children may also be the
consequence of maternal undernutrition in preg-
nancy and while breastfeeding.
In conclusion, our study reveals the severe cost
consequences of iodine, iron, vitamin A, and zinc
deficiencies in young Pakistani children. Most of
these costs are invisible to the parents, as they
will occur over the future lifetime of the child.
As our results identify the areas of highest soci-
eatal costs of MNDs, they may be useful for the
design and the implementation of interventions
aiming to maximize the effect of the available
financial resources. Future research should focus
on further improving the knowledge on the liv-
ing conditions and on the inadequate nutrition
responsible for MNDs. This research could be
strengthened with refined population surveys
collecting richer data on health, nutrition, expo-
sition to policy measures, and socioeconomic
conditions.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest
with respect to the research, authorship, and/or
publication of this article.
Funding
The author(s) disclosed receipt of the following finan-
cial support for the research, authorship, and/or publi-
cation of this article: This work was funded through an
unrestricted grant from Nestle´ Research Center. Addi-
tional direct and in-kind support was received from the
Aga Khan University, the ETH Zurich, and the Zurich
University of Applied Sciences.
References
1. Bougma K, Aboud FE, Harding KB, Marquis GS.
Iodine and mental development of children 5 years
old and under: a systematic review and meta-anal-
ysis. Nutrients. 2013;5(4):1384-1416.
2. Walker SP, Wachs TD, Gardner JM, et al. Child
development: risk factors for adverse outcomes in
developing countries. Lancet. 2007;369(9556):
145-157.
3. Aga Khan University, Nutrition Wing Planning
Commission, Government of Pakistan, UNICEF.
National Nutrition Survey Pakistan 2011. Islama-
bad, Pakistan: Planning Commission, Government
of Pakistan; 2012.
4. Horton S, Steckel RH. Malnutrition. In: Lomborg
B, ed. How Much Have Global Problems Cost the
World? Cambridge, UK: Cambridge University
Press; 2013:247-272.
5. Alderman H. The economic cost of a poor start to
life. J Dev Orig Health Dis. 2010;1(1):19-25.
6. Haddad L, Hawkes C, Udomkesmalee E, et al.
Global Nutrition Report 2015: Actions and
Accountability to Advance Nutrition and Sustain-
able Development. Washington, DC: International
Food Policy Research Institute; 2015.
498 Food and Nutrition Bulletin 38(4)
7. Wieser S, Plessow R, Eichler K, et al. Burden of
micronutrient deficiencies by socio-economic
strata in children aged 6 months to 5 years in the
Philippines. BMC Publ Health. 2013;13(1):1167.
8. Plessow R, Arora N, Brunner B, et al. Social costs
of iron deficiency anemia in 6-59-month-old chil-
dren in India. PLoS One. 2015;10(8):e0136581.
9. National Institute of Population Studies (NIPS)
[Pakistan] and ICF International. Pakistan Demo-
graphic and Health Survey 2012-13. Islamabad,
Pakistan, and Calverton, MD: NIPS and ICF Inter-
national; 2013.
10. Black RE, Victora CG, Walker SP, et al. Maternal
and child undernutrition and overweight in low-
income and middle-income countries. Lancet.
2013;382(9890):427-451.
11. World Health Organization, United Nations Chil-
dren’s Fund, International Council for the Control
of Iodine Deficiency Disorders. Assessment of
Iodine Deficiency Disorders and Monitoring Their
Elimination. A Guide for Programme Managers.
Geneva, Switzerland: World Health Organization;
2007.
12. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A
systematic analysis of global anemia burden from
1990 to 2010. Blood. 2014;123(5):615-624.
13. Rastogi T, Mathers C. Global Burden of Iron
Deficiency Anemia in the Year 2000. Geneva,
Switzerland: World Health Organization; 2002.
14. World Health Organization. Haemoglobin Con-
centrations for the Diagnosis of Anaemia and
Assessment of Severity. Geneva, Switzerland:
World Health Organization; 2011.
15. World Health Organization. Global Prevalence of
Vitamin A Deficiency in Populations at Risk 1995-
2005. WHO Global Database on Vitamin A Defi-
ciency. Geneva, Switzerland: World Health Orga-
nization; 2009.
16. Stoltzfus RJ, Mullany l, Black RE. Iron deficiency
anemia. In: Ezzati M, ed. Comparative Quantifica-
tion of Health Risks: The Global and Regional
Burden of Disease due to 25 Selected Major Risk
Factors. Cambridge, UK: Harvard University
Press; 2004:163-209.
17. Rothman KJ, Greenland S, Lash TL. Modern Epi-
demiology. 3rd ed. Philadelphia, PA: Lippincott,
Williams & Wilkins; 2008.
18. Pakistan minimum wage statistics: Average
monthly earnings of employees. International
Labour Organization; 2017. http://bit.ly/
2swBz4A. Accessed July 2, 2017.
19. Javed SA, Irfan M. Intergenerational Mobility:
Evidence from Pakistan Panel Household Survey.
Vol 53. Islamabad, Pakistan: Pakistan Institute of
Development Economics; 2014:105-133.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS,
Russell LB. Recommendations of the panel on
cost-effectiveness in health and medicine. J Am
Med Assoc. 1996;276(15):1253-1258.
21. Murray CJL, Barber RM, Foreman KJ, et al. Glo-
bal, regional, and national disability-adjusted life
years (DALYs) for 306 diseases and injuries and
healthy life expectancy (HALE) for 188 countries,
1990–2013: quantifying the epidemiological tran-
sition. Lancet. 2015;386(10009):2145-2191.
22. ShiroiwaT,FukudaT, IkedaS,ShimozumaK.QALY
and productivity loss: empirical evidence for “double
counting”. Value Health. 2013;16(4):581-587.
23. Taylor PN, Okosieme OE, Dayan CM, Lazarus JH.
Therapy of endocrine disease: impact of iodine
supplementation in mild-to-moderate iodine defi-
ciency: systematic review and meta-analysis. Eur J
Endocrinol. 2014;170(1):R1-R15.
24. Zimmermann M, Andersson M. Development of a
new framework to estimate the global burden of
disease due to iodine deficiency. In: WHO/CDC.
Methodological Approaches to Estimating Global
and Regional Prevalences of Vitamin and Mineral
Deficiencies. Report on the Joint World Health
Organization/US Centers for Disease Control and
Prevention Technical Consultation. Atlanta, USA,
7–9 December 2010. Geneva, Switzerland: World
Health Organization; 2014:65-77.
25. Lozoff B, Jimenez E, Smith JB. Double burden of
iron deficiency in infancy and low socioeconomic
status. A longitudinal analysis of cognitive test
scores to age 19 years. Arch Pediatr Adolesc Med.
2006;160(11):1108-1113.
26. Stein AJ, Meenakshi JV, Qaim M, Nestel P, Sach-
dev H, Bhutta ZA. Analyzing the health benefits of
biofortified staple crops by means of the disability-
adjusted life years approach: a handbook focusing
on iron, zinc and vitamin A. Washington, DC, and
Cali: HarvestPlus Technical Monograph 4; 2005.
27. Salomon JA, Haagsma JA, Davis A, et al. Dis-
ability weights for the Global Burden of Disease
2013 study. Lancet Glob Health. 2015;3(11):
e712-e723.
Wieser et al 499
28. Brabin BJ, Premji Z, Verhoeff F. An analysis of
anemia and child mortality. J Nutr. 2001;131(2S-
2):636S-648S.
29. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY,
Bhutta ZA. Vitamin A supplementation for pre-
venting morbidity and mortality in children from
6 months to 5 years of age. Cochrane Database
Syst Rev. 2010;(12):CD008524.
30. Mayo-Wilson E, Junior JA, Imdad A, et al. Zinc
supplementation for preventing mortality, morbid-
ity, and growth failure in children aged 6 months to
12 years of age. Cochrane Database Syst Rev.
2014;(5):CD009384.
31. Horton S, Ross J. The economics of iron defi-
ciency. Food Pol. 2003;28(1):51-75.
32. Vos T, Barber RM, Bell B, et al. Global, regional,
and national incidence, prevalence, and years lived
with disability for 301 acute and chronic diseases
and injuries in 188 countries, 1990-2013: a sys-
tematic analysis for the Global Burden of Disease
Study 2013. Lancet. 2015;386(9995):743-800.
33. Lozoff B, Beard J, Connor J, Barbara F, Georgieff
M, Schallert T. Long-lasting neural and behavioral
effects of iron deficiency in infancy. Nutr Rev.
2006;64(5 pt 2):34-91.
34. McCann JC, Ames BN. An overview of evidence
for a causal relation between iron deficiency dur-
ing development and deficits in cognitive or beha-
vioral function. Am J Clin Nutr. 2007;85(4):
931-945.
35. Sachdev H, Gera T, Nestel P. Effect of iron supple-
mentation onmental andmotor development in chil-
dren: systematic review of randomised controlled
trials. Public Health Nutr. 2005;8(2):117-132.
36. Akhtar S, Ahmed A, Randhawa MA, et al. Preva-
lence of vitamin A deficiency in South Asia:
causes, outcomes, and possible remedies. J Health
Popul Nutr. 2013;31(4):413-423.
37. Life expectancy at birth, total (years) World Bank;
2017. http://bit.ly/2cgHlgD. Accessed July 2, 2017.
38. Smith D, Garavelle H. The practice of discounting
economic evaluations of health care interventions.
Int J Tech Assess Health Care. 2001;17(2):
236-243.
39. Murray CJ, Ezzati M, Flaxman AD, et al. GBD
2010: design, definitions, and metrics. Lancet.
2012;380(9859):2063-2066.
40. GDP per capita growth (annual %) 1990-2016.
World Bank; 2015. http://bit.ly/2tBLfdh.
Accessed July 20, 2017.
41. Labour force participation rates and un-
employmed rates by age, sex and area. Pakistan
Bureau of Statistics; 2008-09. http://bit.ly/
2t7da4h. Accessed July 20, 2017.
42. Labor force participation rate, total (% of total
population ages 15-64) (modeled ILO estimate)
World Bank; 2017. http://bit.ly/2tGznHw.
Accessed July 20, 2017.
43. Unemployment, total (% of total labor force)
(modeled ILO estimate) World Bank; 2017.
http://bit.ly/2uzzz7Z. Accessed July 20, 2017.
44. Brennan A, Akehurst R. Modelling in health eco-
nomic evaluation. What is its place? What is its
value? Pharmacoeconomics. 2000;17(5):445-459.
45. Ross JH, S. Economic Consequences of Iron Defi-
ciency.Ottawa,Canada:Micronutrient Initiative;1998.
46. Walker N, Tam Y, Friberg I. Overview of the
Lives Saved Tool (LiST). BMC Publ Health.
2013;13(suppl 3):S1.
47. Burkhalter BR, Abel E, Aguayo V. Nutrition advo-
cacy and national development: the PROFILES
programme and its application. Bull World Health
Organ. 1999;77(5):407-415.
48. Gaffey MF, Baloch Q, Rana M, et al. Pakistan food
fortification scoping study. Washington, DC:
PATH; 2014.
49. Bhutta ZA, Das JK, Rizvi A, et al. Evidence-based
interventions for improvement of maternal and
child nutrition: what can be done and at what cost?
Lancet. 2013;382(9890):452-477.
500 Food and Nutrition Bulletin 38(4)
